awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28972291-3C15F8B2-C977-4EF0-9B52-080E573DA869
Q28972291-3C15F8B2-C977-4EF0-9B52-080E573DA869
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28972291-3C15F8B2-C977-4EF0-9B52-080E573DA869
Evolving Therapies and FAK Inhibitors for the Treatment of Cancer
P2860
Q28972291-3C15F8B2-C977-4EF0-9B52-080E573DA869
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28972291-3C15F8B2-C977-4EF0-9B52-080E573DA869
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5ac9efbcfb50a6665fa95ebc152b16ae7df27569
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.